Skip to main content
. Author manuscript; available in PMC: 2023 Dec 26.
Published in final edited form as: Psychopharmacology (Berl). 2022 Mar 7;239(6):1679–1687. doi: 10.1007/s00213-022-06104-w

Figure 3.

Figure 3.

Ethanol dose (g/kg) consumed during the acquisition of two-bottle choice ethanol self-administration and during ethanol re-exposures following a treatment period with vehicle (Veh), the 5-HT2A antagonist M100907 (M100, 1 mg/kg, i.p.) and/or ayahuasca (100 mg/kg, i.g.). Each time-point is an average of 3 sessions within the same phase (i.e., 3 acquisition sessions or 3 re-exposure sessions). Data are shown as mean±SEM. υp<0.05 compared to the same group during D1-D6; #p<0.05 compared to Veh-Veh.